Additional file 3: of A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (HumiraÂŽ) in the treatment of active rheumatoid arthritis

Additional file 3: of A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (HumiraÂŽ) in the treatment of active rheumatoid arthritis

Consolidated Standards of Reporting Trials (CONSORT) flow diagram of patient progress in the two treatment arms. aPatients may screen fail for more than one reason. bPatients may be excluded from the per-protocol population for more than one reason. Abbreviation: Adalimumab-EU adalimumab sourced fro...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Fleischmann, Roy, Alten, Rieke, Pileckyte, Margarita, Lobello, Kasia, Hua, Steven, Cronenberger, Carol, Alvarez, Daniel, Bock, Amy, K. Sewell
Format: Bild
Sprache:eng
Schlagworte:
Biological Sciences not elsewhere classified
Biotechnology
Cancer
Developmental Biology
Environmental Sciences not elsewhere classified
FOS: Biological sciences
FOS: Earth and related environmental sciences
FOS: Sociology
Medicine
Pharmacology
Sociology
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Consolidated Standards of Reporting Trials (CONSORT) flow diagram of patient progress in the two treatment arms. aPatients may screen fail for more than one reason. bPatients may be excluded from the per-protocol population for more than one reason. Abbreviation: Adalimumab-EU adalimumab sourced from the European Union. (PNG 171 kb)
DOI:10.6084/m9.figshare.6973424